HLA class II alleles in Romanian patients with chronic hepatitis C

Gheorghe, Loredana; Rugină, Sorin; Dumitru, Irina Magdalena; Franciuc, Irina; Martinescu, Alina; Balas, Iulia

doi:10.11599/germs.2015.1070

Cited by 2 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified a significant inverse correlation between the duration of HCV infection and the quantitative decrease in liver stiffness, r s =-0.326, p=0.017, N=53, but this association was not statistically significant when comparing the qualitative regression in liver fibrosis, despite the fact that patients who achieved a one stage decrease in fibrosis had a slightly lower median (IQR) duration of HCV infection, 12 (7)(8)(9)(10)(11)(12)(13)(14)(15)(16) years, compared with those who did not achieve regression of liver fibrosis, 13.5 (9-16) years (U=320.5, p=0.578, r=0.08).…”

Section: Duration Of Hcv Infectionmentioning

confidence: 85%

“…We also assessed whether there is an association between the regression of liver fibrosis with classical prognostic factors previously used for calculating the chance of obtaining SVR following interferon-based treatment, such as: younger age (7,8), female gender (9), IL28B CC rs12979860 (10) or other genetic polymorphisms (11,12), baseline viral load below 600,000 IU/mL (13,14), absence of diabetes mellitus (15), shorter duration of HCV infection (16) calculated as the time (years) since the first positive anti-HCV test, and absence of surrogate markers for advanced liver disease at baseline.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Nițescu

Vâjâitu

Săndulescu

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

Section: Duration Of Hcv Infectionmentioning

confidence: 85%

Section: Methodsmentioning

confidence: 99%

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Nițescu

Vâjâitu

Săndulescu

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…Romero et al (23) reported no association of HLA polymorphism DQB1*0301 with SR and CI groups. In a Romanian cohort of chronic HCV patients, Gheorghe et al observed that HLA-DRB1*0301 had a high frequency (14.8%) in NR patients while alleles DRB1*0701 (11.1%), DRB1*11 (22.2%), and DRB1*0101 (16.7%) were prevalent in sustained virologic responders (SVR) (10). On the other hand, it was interesting that the SNPs in TNF-α were not associated with any patient category.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, IFN-L4 genotypes (rs12979860 C/C and ss469415590 TT/TT) were described as the predictors of response to IFN and RBV therapy (11,12). Allelic polymorphisms HLA-DRB1*0301, DRB1*0701, and DRB1*11 showed to have significant roles in therapeutic response to HCV infection in Romanian patients (10). Likewise, HLA-A01 and HLA-B38 were associated with response to IFN-RBV therapy in HCV-infected Egyptian patients (13).…”

Section: Introductionmentioning

confidence: 97%

“…RNA is indicative of non-clearance, which could be due to ineffective recognition of viral antigen by T cells or failure in the treatment (4,8). Moreover, human leukocyte antigen (HLA) molecules such as HLA-DQ , -DR, and -DP trigger the immune response via CD4 T cells (9,10). Similarly, IFN-L4 genotypes (rs12979860 C/C and ss469415590 TT/TT) were described as the predictors of response to IFN and RBV therapy (11,12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel Polymorphism in the Promoter Region of HLA-DQB1 Is a Predictor of Anti-HCV Therapy Response

Arshad

Jalil

Raza

et al. 2019

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) is a major cause of chronic liver infection, which may lead to liver cirrhosis, fibrosis, and hepatocellular carcinoma while about one-fourth of the infected patients recover spontaneously. The host immune response remains decisive in the outcomes of antiviral treatment. Single nucleotide polymorphisms (SNPs) at the genes within the human leukocyte antigen (HLA) cluster are associated with differential immune response and treatment outcomes. Objectives: This study aimed to determine the association of SNPs in Tumor necrosis factor-alpha (TNF-α) and HLA genes (HLA-DRB1 and HLA-DQB1) with the outcomes of HCV infection and anti-HCV therapy. Methods: The study included 245 HCV-infected patients visiting a tertiary care hospital, located in Islamabad, Pakistan. Viral quantification and genotyping were performed by real-time PCR. Twenty SNPs in TNF-α, HLA-DRB1, and HLA-DQB1 were sequence-genotyped by the Sanger method in 180 patients. Multivariate logistic regression was performed to establish the association of SNPs with spontaneous clearance of the virus and response to anti-HCV therapy. Results: Five out of 20 SNPs were novel. Allelic variants at three different locations (HLA-DRB1, rs2308802; HLA-DQB1,-8447, and HLA-DQB1,-8471) showed significant associations with two groups of HCV patients receiving anti-HCV treatment (responsive and nonresponsive). Multivariate analyses disclosed that genotype A/A at HLA-DQB1 (-8471) was a significant predictor of positive response to treatment although in the presence of the variant at HLA-DRB1 (rs230880) (P = 0.004). However, no association was detected between the haplotypes constructed for the three sets of SNPs and different categories of patients. Conclusions: This study established a novel SNP HLA-DQB1(-8471) as an important predictor of an effective response to anti-HCV therapy in HCV-infected Pakistani patients. Prescreening of this variant before therapy would benefit HCV patients.

show abstract

HLA class II alleles in Romanian patients with chronic hepatitis C

Cited by 2 publications

References 11 publications

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Novel Polymorphism in the Promoter Region of HLA-DQB1 Is a Predictor of Anti-HCV Therapy Response

Contact Info

Product

Resources

About